TIGAN INJECTION Rx
Generic Name and Formulations:
Trimethobenzamide HCl 100mg/mL; for IM inj.
Indications for TIGAN INJECTION:
Treatment of post-op or gastroenteritis-associated nausea and vomiting.
Use lowest effective dose. 200mg IM 3–4 times daily.
Acute dystonic reactions. Extrapyramidal symptoms. May mask other serious disorders (eg, encephalopathy, metabolic imbalance). Children (Reye's syndrome). Monitor for hepatic impairment; discontinue if occurs. Renal impairment. Elderly. Pregnancy. Nursing mothers.
Potentiated by alcohol (avoid), other CNS depressants (eg, sedatives, hypnotics, opiates, anxiolytics, antipsychotics, anticholinergics); monitor.
Parkinson-like symptoms, drowsiness, blood dyscrasias, blurred vision, coma, seizures, depression, diarrhea, disorientation, dizziness, jaundice, hypotension (inj), headache, muscle cramps, opisthotonos; hepatotoxicity, hypersensitivity reactions.
Caps—100; Single-use vials (2mL)—25; Multi-dose vial (20mL)—1
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Immune Checkpoint Inhibitors for NSCLC: Current and Future Approaches
- Can A Consortium of Hospitals Help To Reduce Drug Prices?
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- Erdafitinib Granted FDA Breakthrough Therapy Designation for Urothelial Carcinoma
- NSCLC: Stratifying Patients With Complex EGFR Mutations
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma
- NSCLC: Pretreatment Weight Loss May Be Linked to Socioeconomic Status
- Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC
- Model May Identify Patients With Gastric Cancer Likely To Benefit From Chemotherapy